Dosing & Uses
COVID-19 (Investigational)
Pending EUA for treatment of mild-to-moderate coronavirus disease 2019 (COVID-19)
Next:
Pharmacology
Mechanism of Action
Amubarvimab/romlusevimab are monoclonal antibodies with non-overlapping epitope binding regions enabling a high degree of neutralization activity against SARS-CoV-2
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.